Bobak R. Azamian Sells 8,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) CEO Bobak R. Azamian sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $13.79, for a total transaction of $110,320.00. Following the transaction, the chief executive officer now owns 1,080,536 shares of the company’s stock, valued at approximately $14,900,591.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tarsus Pharmaceuticals Trading Down 5.0 %

Shares of TARS opened at $12.75 on Friday. The company has a quick ratio of 16.40, a current ratio of 16.40 and a debt-to-equity ratio of 0.10. Tarsus Pharmaceuticals, Inc. has a twelve month low of $10.80 and a twelve month high of $19.66. The firm’s 50 day moving average price is $15.07 and its two-hundred day moving average price is $15.88.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Tarsus Pharmaceuticals in a report on Wednesday.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. UBS Group AG lifted its stake in Tarsus Pharmaceuticals by 37.0% in the first quarter. UBS Group AG now owns 4,226 shares of the company’s stock valued at $71,000 after buying an additional 1,142 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Tarsus Pharmaceuticals by 13.0% in the fourth quarter. JPMorgan Chase & Co. now owns 11,351 shares of the company’s stock valued at $167,000 after buying an additional 1,309 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Tarsus Pharmaceuticals by 3.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 48,583 shares of the company’s stock valued at $818,000 after buying an additional 1,402 shares in the last quarter. State Street Corp lifted its stake in Tarsus Pharmaceuticals by 2.4% in the first quarter. State Street Corp now owns 132,883 shares of the company’s stock valued at $2,235,000 after buying an additional 3,141 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Tarsus Pharmaceuticals by 33.8% in the fourth quarter. Bank of America Corp DE now owns 15,544 shares of the company’s stock valued at $228,000 after buying an additional 3,924 shares in the last quarter. Institutional investors own 76.82% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

(Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.